Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Mary Strasberg-Rieber"'
Autor:
Mary Strasberg-Rieber, Manuel Rieber
Publikováno v:
Biochemical Pharmacology. 88(2):169-177
Background Most breast cancers express the estrogen receptor alpha (ERα + ), harbor wt TP53 , depend on estrogen/ERK signalling for proliferation, and respond to anti-estrogens. However, concomittant activation of the epidermal growth factor recepto
Autor:
Mary Strasberg-Rieber, Manuel Rieber
Publikováno v:
Biochemical Pharmacology. 84(12):1563-1570
Hypoxia is part of the tumor microenvironment favoring cancer resistance to chemotherapy mediated by mutations in the tumor suppressor p53 gene (TP53), or by conformational wt TP53 dysfunction. Since it is important to suppress tumor adaptation to hy
Publikováno v:
BMC Cancer
Background The metabolic inhibitor 3-bromopyruvate (3-BrPA) is a promising anti-cancer alkylating agent, shown to inhibit growth of some colorectal carcinoma with KRAS mutation. Recently, we demonstrated increased resistance to 3-BrPA in wt p53 tumor
Publikováno v:
Cancer Biology & Therapy. 12:647-656
Dominant-negative (DN) p53 mutations in the tumor suppressor p53 gene partly contribute to human cancer progression by inactivating the remaining wild type allele. Since tumor cells face glucose and growth factor shortage when growing distant from si
Publikováno v:
Journal of Medicinal Chemistry. 53:1627-1635
In contrast to other metal-dithiocarbamate [DEDTC] complexes, the copper-DEDTC complex is highly cytotoxic, inducing oxidative stress, preferentially in tumor cells. Because nitric oxide (NO) forms adducts with Cu[DEDTC](2), we investigated whether N
Publikováno v:
Biochemical Pharmacology. 74:841-850
Copper and two molecules of diethyl dithiocarbamate [DEDTC] form the Cu[DEDTC](2) complex, which shows cytotoxicity against melanoma and carcinoma cells, making it a potentially useful anti-cancer agent. The differential response to Cu[DEDTC](2) in s
Autor:
Manuel Rieber, Mary Strasberg Rieber
Publikováno v:
International Journal of Cancer. 118:1135-1143
MEK1/2 inhibitors like U0126 can potentiate or antagonize the antitumor activity of cytotoxic agents such as cisplatin, paclitaxel or vinblastine, depending on the drug or the target cells. We now investigated whether U0126, differentially regulates
Publikováno v:
Cancer Biology & Therapy. 4:329-335
Solid tumors are often placed under stress conditions, such as glucose starvation which may result in topoisomerase II drug resistance. In this study, we investigated whether glucose deprivation or substitution by fructose regulates tumor cell apopto
Publikováno v:
International Journal of Cancer. 112:376-384
Ketoconazole (KTZ) has been used as a second-line agent in hormone-refractory cancer therapy. Since transition metal complexes including those of Ru(III), show important anticancer activity with limited toxicity, we investigated the potential antitum
Autor:
Manuel Rieber, Mary Strasberg Rieber
Publikováno v:
Biochemical Pharmacology. 65:1593-1601
Redox imbalance due to oxidative stress or excessive antioxidant levels can alter apoptotic responses. Recently, antioxidants like N-acetylcysteine (NAC) were reported to inhibit H(2)O(2)-mediated necrotic cell death, although they were inactive agai